1) Plasma plasminogen inhibitor
纤溶酶原抑制物
2) plasminogen activator inhibitor-1
纤溶酶原激活物抑制物
1.
Objective:To analyze the plasma levels of tissue plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1) in patients with coronary heart disease(CHD) and to assess its clinical implications.
方法:回顾性分析本院222例冠心病患者血浆组织型纤溶酶原激活物(t-PA)及纤溶酶原激活物抑制物-1(PAI-1)水平。
2.
ObjectiveTo evaluate the plasminogen activator system (plasminogen activator inhibitor-1 and tissue plasminogen activator) in women with PCOS and compared in groups .
目的:探讨纤溶酶原激活物抑制物-1(PAI-1)和组织型纤溶酶原激活物(t-PA)的高低与多囊卵巢综合征(polycystic ovary syndrome, PCOS)患者病变发展之间的关系以探寻一较好的监测指标。
3.
Objective To investigate the role of rosiglitazone in improving blood lipids and proteinuria in rats with Type 2 diabete,and the effect of rosiglitazone on expressions of plasminogen activator inhibitor-1 in kidney of streptozotocin-diabetic rats.
目的研究罗格列酮对2型糖尿病大鼠血糖血脂的影响及肾皮质纤溶酶原激活物抑制物1(PAI-1)表达的作用。
3) plasminogen activator inhibitor
纤溶酶原激活物抑制物
1.
Objective To observe the influence of Shenluotong on the protein expression of plasminogen activator inhibitor 1(PAI-1) in kidney remaining tissue in rats with kidney failure induced by 5/6 of nephrectomy.
目的观察肾络通对5/6肾切除肾衰竭大鼠残余肾组织纤溶酶原激活物抑制物-1(PAI-1)蛋白表达的影响。
2.
The activities of tissue plasminogen activator(tPA),plasminogen activator inhibitor(PAI) and plasminogen(PLG) in plasma were determined by chromogenic substrate assay,and thrombi weight was measured.
先给大鼠喂药后以FeCl3诱导左侧颈总动脉血栓形成,以发色底物法测定血浆组织型纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物(PAI)和纤溶酶原(PLG)活性,并测定血栓质量。
3.
Objective To investigate the changes of serum plasminogen activator inhibitor(PAI),D-dimer and thrombomodulin(TM),and the relationship between these changes and phlegm syndrome or blood-stasis syndrome in patients with acute cerebral infarction.
目的探讨急性脑梗死患者血浆纤溶酶原激活物抑制物(PAI)、D-二聚体、血栓调节蛋白(TM)变化与中医痰证、血瘀证变化的关系。
4) Plasminogen activator inhibitor 1
纤溶酶原激活物抑制物
1.
Objective To study the changes of tissue plasminogen activator (t-PA), plasminogen activator inhibitor 1 (PAI-1), and soluble thrombomodulin (sTM) induced by dengue 2 virus (D 2V) infection of vascular endothelial cells.
方法 应用D2 V感染生长良好的第2、3代脐静脉内皮细胞以观察内皮细胞在表达组织纤溶酶原激活物(tPA)、纤溶酶原激活物抑制物1(PAI 1)、凝血酶调节蛋白(TM)等分子变化。
5) plasminogen activator inhibitor
纤溶酶原激活物抑制剂
1.
Objective To study the effect of Shuxuetong injection on brain microvascular endothelial cell secreting tissue-type plasminogen activator(t-PA) and plasminogen activator inhibitor-1(PAI-1).
目的研究疏血通注射液对脑微血管内皮细胞(BMECs)分泌组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂-1(PAI-1)的影响。
2.
The therapeutic effect and changes of neurofunction deficit score, tissue type plasminogen activator (tPA), plasminogen activator inhibitor (PAI), antithrombin Ⅲ (AT Ⅲ), th.
观察两组患者治疗后有效率 ,治疗前后神经功能缺损评分、组织型纤溶酶原激活剂 (tPA)、纤溶酶原激活物抑制剂 (PAI)、抗凝血酶 Ⅲ (AT Ⅲ )、血栓素B2 (TXB2 )及 6 -酮 -前列腺素F1α(6 keto PGF1α)的变化。
3.
The plasma tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI) activities were determined by chrimogenic substrate method.
方法:采用Olimpus-AU5400全自动生化分析仪测定53例SCI患者和55例健康者(对照组)血清Lp(α)水平,用发色底物法检测血浆组织型纤溶酶原激活物(t-PA)和纤溶酶原激活物抑制剂(PAI)活性,并对SCI患者的血清Lp(α)水平与血浆t-PA和PAI活性进行相关分析。
6) plasminogen activator inhibitor-1
纤溶酶原激活物抑制剂
1.
AIM:To observe the effects of angiotensin Ⅱ(AngⅡ) on PAI-1 (plasminogen activator inhibitor-1) and tPA (tissue type plasmingen activator) releases in isolated aorta and changes of fibrinolytic function in different states of RAS (renin-angiotensin system) in rats.
目的 :观察血管紧张素 (Ang )对大鼠主动脉纤溶酶原激活物抑制剂 (PAI- 1)、组织型纤溶酶原激活物(t PA)活性的影响及不同肾素活性状态下纤溶功能的变化。
补充资料：纤溶酶原
分子式：
CAS号：
性质：无活性纤溶酶前身物。在生理条件下只要有小量纤溶酶生成，就会被抑制剂α2抗纤溶酶迅速钝化。纤溶酶原同纤维蛋白原和纤维蛋白结合形成血块时，渗入到血块中，在此情况下激活形成的纤溶酶不受α2抗纤溶酶抑制。组织中的各种纤溶酶原激活剂都是丝氨酸蛋白酶，水解纤溶酶原多肽链上的Arg-Val肽键，生成有活性的纤溶酶，可使纤维蛋白水解成可溶性降解产物，使血块溶解。
CAS号：
性质：无活性纤溶酶前身物。在生理条件下只要有小量纤溶酶生成，就会被抑制剂α2抗纤溶酶迅速钝化。纤溶酶原同纤维蛋白原和纤维蛋白结合形成血块时，渗入到血块中，在此情况下激活形成的纤溶酶不受α2抗纤溶酶抑制。组织中的各种纤溶酶原激活剂都是丝氨酸蛋白酶，水解纤溶酶原多肽链上的Arg-Val肽键，生成有活性的纤溶酶，可使纤维蛋白水解成可溶性降解产物，使血块溶解。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条